News & Articles 21/12/2023 Our Network Wainua (eplontersen) granted first-ever regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis US FDA approval based on NEURO-TTRansform Phase III results showing Wainua demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life. Additional regulatory reviews underway in rest of world.
